Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-08-24), Sinovac Biotech's share price is $6.47. Sinovac Biotech's Book Value per Share for the quarter that ended in Jun. 2026 was $62.70. Hence, Sinovac Biotech's PB Ratio of today is 0.10.
Warning Sign:
Sinovac Biotech Ltd stock PB Ratio (=0.1) is close to 3-year high of 0.1.
The historical rank and industry rank for Sinovac Biotech's PB Ratio or its related term are showing as below:
SVA'
s PB Ratio Range Over the Past 10 Years
Min: 0.05 Med: 0.86 Max: 3.94
Current: 0.1
During the past 13 years, Sinovac Biotech's highest PB Ratio was 3.94. The lowest was 0.05. And the median was 0.86.
SVA's PB Ratio is not ranked
in the Biotechnology industry.
Industry Median: 2.95
vs SVA: 0.10
During the past 12 months, Sinovac Biotech's average Book Value Per Share Growth Rate was 3.10% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -11.70% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 38.70% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was 63.90% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Sinovac Biotech was 435.60% per year. The lowest was -11.70% per year. And the median was 27.95% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Sinovac Biotech PB Ratio Related Terms
Sinovac Biotech PB Ratio Historical Data
* Premium members only.
The historical data trend for Sinovac Biotech's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Sinovac Biotech's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sinovac Biotech PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Sinovac Biotech's PB Ratio distribution charts can be found below:
* The bar in red indicates where Sinovac Biotech's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
Sinovac Biotech's PB Ratio for today is calculated as follows:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Sinovac Biotech (SVA) has a PB Ratio of 0.10 as of Aug. 24, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Sinovac Biotech and its competitors. This is 88% below median its historical median of 0.86. Over the past decade, Sinovac Biotech's PB Ratio has ranged from 0.05 to 3.94.
Is Sinovac Biotech's PB Ratio too high?
Sinovac Biotech's current PB Ratio of 0.10 is 88% below median its 10-year median of 0.86. Over the past 10 years, this metric has ranged from a low of 0.05 to a high of 3.94. The Biotechnology industry median PB Ratio is 2.95. Sinovac Biotech's value of 0.10 is 96.6% below this industry median. Overall, Sinovac Biotech has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Sinovac Biotech's PB Ratio compare to INBX and HLVX?
Sinovac Biotech's PB Ratio of 0.10 can be compared against companies in the Biotechnology industry. The industry median PB Ratio is 2.95. Sinovac Biotech's value of 0.10 is 96.6% below this benchmark. Historically, Sinovac Biotech's own PB Ratio has ranged from 0.05 to 3.94 over the past decade. While the company's 10-year median is 0.86 vs. the industry median of 2.95, Sinovac Biotech has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.95, based on 1,215 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sinovac Biotech's current PB Ratio of 0.10 is 96.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Sinovac Biotech and its competitors. For the Biotechnology industry, the median PB Ratio is 2.95 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sinovac Biotech's current PB Ratio is 0.10, which is 88% below median its own 10-year median of 0.86. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sinovac Biotech stock overvalued right now?
Sinovac Biotech (SVA) has a current PB Ratio of 0.10. The current PB Ratio is 0.10, which is 88% below median its 10-year median of 0.86 and 96.6% below the Biotechnology industry median of 2.95. Sinovac Biotech's overall GF Score™ is 12/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Sinovac Biotech (SVA), the current PB Ratio is 0.10 as of Aug. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Sinovac Biotech Ltd is a fully integrated China-based biopharmaceutical company focused on the research, development, manufacturing and commercialization of vaccines for the prevention of human infectious diseases, including certain diseases with unmet medical needs. It has developed a comprehensive vaccine portfolio covering hepatitis A, hepatitis B, hand, foot and mouth disease ("HFMD") caused by enterovirus 71 ("EV71"), seasonal and pandemic influenza, COVID-19, pneumococcal disease, poliomyelitis, mumps, varicella, rabies and tetanus. The Company operates exclusively in the research, development, manufacture, and commercialization of vaccines sector. The Company's business is considered as operating in one segment. It has presence in Chinese Mainland, and Outside Chinese Mainland.
12GF Score
Get the complete analysis for SVA
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SVA has been successfully added to your 
